How Can We Help?
Skip to content
Researcher looking at a book
Access ADME Logo

Webinars

Nov. 2nd COVID-19 Drug Repurposing Webinar: Ion Channel Targets of Dexamethasone and Sex Steroid Hormones in Airway Disease

Presenter: Dr. Brian Harvey, Emeritus Professor of Molecular Medicine at the Royal College of Surgeons in Ireland Key concepts discussed in this webinar will include: Background...

Oct. 5th Webinar: Role of UDP-Glucuronosyltransferases (UGTs) in Drug Metabolism and Drug-Drug Interactions

Presenter: Maciej Czerwinski, Ph.D., SEKISUI XenoTech Director of Scientific Consulting Abstract: The importance of glucuronidation for metabolism of xenobiotics in humans is illustrated by the abundance...

Sept. 21st Webinar: Hepatocellular Drug Disposition Profiling Using Sandwich-Cultured Hepatocytes by D-PREX Assay

Presenter: Dr. Katsuhiro Kanda, Senior Engineer in Bio Systems Design at Hitachi High-Tech Corporation Abstract: D-PREXⓇ is an assay methodology to evaluate total hepatocellular drug dispositions...

Underprediction of Drug Clearance by Aldehyde Oxidase (AO)–Mediated Drug Metabolism: Important Considerations for In Vitro Assessment

Presenter: Pallavi Limaye, Ph.D., DABT, SEKISUI XenoTech Director of Scientific Consulting Abstract: Aldehyde oxidase (AO) enzyme has gained increasing attention in drug development as one of...

Addressing Unique Challenges with Custom In Vitro Test Systems

Presenter: Zell Woodworth, Division Director of Products at SEKISUI XenoTech Abstract: Sometimes, standard products just don’t fit the objective of a unique assay. In this webinar,...

The Role of In Vitro Assays in Selecting the Right Species for Your Small Molecule Program

Presenters: Andrew G. Taylor, Ph.D., Manager of Technical Support for Services at SEKISUI XenoTech and Scott Boley, Ph.D., DABT, Senior Vice President of Research at Sinclair...

Red Blood Cell Partitioning Studies to Improve Accuracy in Pharmacokinetics (PK) Calculations

Presenter: Steven McGreal, Ph.D, Study Director at SEKISUI XenoTech Abstract: Pharmacokinetic (PK) parameters of a new drug candidate are typically determined by measuring the drug’s...

An Overview of Non CYP-Mediated Metabolism Pathways and In Vitro Evaluation Strategies

Presenter: Brian Ogilvie, Ph.D, Vice President of Scientific Consulting at SEKISUI XenoTech Abstract: Although cytochrome P450 (CYP)-mediated metabolism continues to be of major importance for...

2C or Not 2C: CYP2C Induction Studies for Successful Preclinical Risk Assessment

As a part of IND-enabling preclinical drug development studies companies are required to meet regulatory expectations to evaluate the induction potential of their compound for the cytochrome P450 CYP enzymes CYP1A2, 2B6, 2C8, 2C19 and 3A4.  While only CYP1A2, 2B6 and 3A4 must be assessed in the initial induction panel, any observed induction of CYP3A4 requires further investigation of induction potential for enzymes in the CYP2C family due to crosstalk between the PXR and CAR nuclear receptor pathways.  This webinar will focus on CYP2C induction and will emphasize when to include CYP2C induction in a study, how to design the study to generate meaningful data and meet the regulatory requirements, what endpoints to measure, and how to interpret results.

In Vitro Cholestatic DILI & Mitochondrial Toxicity Studies to Assess Hepatotoxicity

Drug-Induced Liver Injury (DILI) incidents account for more than 10% of all cases of acute liver failure, posing a major clinical and regulatory challenge. While the cause of DILI is multifactorial and difficult to predict, there are known mechanisms...

What topic would you like to hear about?

Our experts are constantly on the hunt for new and exciting topics to present on, and nothing helps us figure out what you want to hear more than requests and feedback! Use our form to submit your request so we can continue producing educational materials you look forward to

Access ADME